Table 2.
Adjusted Odds Ratios of Adverse Outcomes at 3-month According to Eosinophil changes After Intravenous Thrombolysis.
| Outcomes | Increase or no change (n = 229) | 0< decrease ≤25% (n = 88) | 25%< decrease ≤50% (n = 102) | 50%< decrease ≤75% (n = 66) | 75%< decrease ≤100% (n = 138) | Each 10% decrease in Eosinophils |
|---|---|---|---|---|---|---|
| Poor outcome (n.%) | 34 (14.85) | 13 (14.77) | 24 (23.53) | 23 (34.85) | 73 (52.90) | |
| Crude Model |
1 | 0.994 (0.497–1.987) | 1.765 (0.983–3.167) | 3.068 (1.644–5.724) | 6.441 (3.929–10.560) | 1.114 (1.075–1.155) |
| Model 1 | 1 | 0.987 (0.484–2.016) | 1.841 (1.005–3.373) | 2.890 (1.505–5.549) | 5.971 (3.550–10.402) | 1.105 (1.065–1.147) |
| Model 2 | 1 | 0.904 (0.429–1.904) | 1.822 (0.970–3.423) | 2.681 (1.350–5.326) | 5.484 (3.150–9.547) | 1.094 (1.053–1.137) |
| Model 3 | 1 | 0.802 (0.358–1.797) | 1.659 (0.845–3.257) | 1.880 (0.889–3.977) | 2.585 (1.370–4.877) | 1.045 (1.007–1.084) |
| Death (n.%) | 3 (1.31) | 4 (4.55) | 1 (0.98) | 6 (9.09) | 41 (29.71) | |
| Crude Model |
1 | 3.587 (0.786–16.365) | 0.746 (0.077–7.258) | 7.533 (1.830–31.006) | 31.842 (9.628–105.313) | 1.343 (1.225–1.472) |
| Model 1 | 1 | 3.664 (0.776–17.315) | 0.782 (0.079–7.752) | 6.772 (1.595–28.749) | 28.069 (8.228–95.758) | 1.316 (1.195–1.448) |
| Model 2 | 1 | 2.820 (0.522–15.224) | 0.844 (0.084–8.511) | 6.275 (1.422–27.690) | 27.004 (7.590–96.075) | 1.302 (1.176–1.443) |
| Model 3 | 1 | 2.781 (0.430–18.006) | 0.855 (0.074–00.928) | 5.455 (1.032–28.846) | 13.836 (3.257–58.769) | 1.190 (1.071–1.322) |
Model 1, adjusted for age, sex.
Model 2, adjusted for age, sex, current smoking, history of hypertension, atrial fibrillation, stroke and triglycerides.
Model 3, adjusted for Model 2 and further adjusted for admission NIHSS scores.